Skip to content

Clinical trials

Seizures trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Seizures Clear all

713 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20008
20016
20029
20038
200417
200524
200629
200726
200822
200930
201031
201124
201217
201328
201416
201526
201634
201736
201840
201925
202031
202131
202227
202328
202440
202540
202619

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed417
Recruiting84
Terminated72
Unknown status61
Active, not recruiting26
Withdrawn24
Not yet recruiting19
Enrolling by invitation7
Suspended2
Available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)32
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.19
Eisai Inc.16
SK Life Science, Inc.15
GlaxoSmithKline14
UCB Pharma13
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12
Jazz Pharmaceuticals11
University of Alabama at Birmingham11
Eisai Co., Ltd.10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Seizures713
Epilepsy402
Epilepsies, Partial76
Drug Resistant Epilepsy36
Status Epilepticus27
Brain Diseases24
Lennox Gastaut Syndrome22
Epilepsies, Myoclonic18
Brain Injuries, Traumatic17
Epilepsy, Generalized16

Trials

Showing 76 to 100 of 713. Each trial links to its page on Pharma Observatory.

613 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.